Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
J Cell Biochem ; 118(5): 1097-1107, 2017 05.
Article in English | MEDLINE | ID: mdl-27608167

ABSTRACT

The objective of this study was to evaluate complex biological properties of human stem cells isolated from adipose tissue (ASCs) harvested utilizing different methods: surgical resection (R), power-assisted liposuction (PAL), and laser-assisted liposuction (LAL). ASCs were isolated from healthy donors, due to surgical resection, power-, and laser-assisted liposuction. Isolated cells were characterized by their clonogenicity, proliferation rate, doubling time, multilineage differentiation, and senescence potential. The average number of ASCs from 1g/1 ml of solid adipose tissue/lipoaspirate was 2.9 × 105 ± 2.4 × 105 , 1.1 × 105 ± 0.8 × 105 , and 1.2 × 105 ± 0.7 × 105 , respectively, for ASCsR, ASCsPAL, and ASCsLAL. However, number of colonies formed by ASCsR and ASCsPAL was significantly higher compared to the average number of colonies formed by ASCsLAL. Also, in comparison to other analyzed cell groups, ASCsPAL obtained the highest proliferative activity. All analyzed cells were characterized by stable expression of CD90 and CD44 markers during prolonged culture. Expression of CD34 and CD45 markers was decreasing in subsequent passages. Presented study shows that different ASCs collection method affects some basic characteristics of these cells, such as number of isolated cells, clonogeneity, or doubling time. J. Cell. Biochem. 118: 1097-1107, 2017. © 2016 Wiley Periodicals, Inc.


Subject(s)
Adipocytes/cytology , Adipose Tissue/surgery , Lipectomy/methods , Specimen Handling/methods , Stem Cells/cytology , Adipose Tissue/cytology , Cell Count , Cell Differentiation , Cell Proliferation , Cell Survival , Cells, Cultured , Female , Healthy Volunteers , Humans
2.
Arch Immunol Ther Exp (Warsz) ; 64(6): 443-454, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27178663

ABSTRACT

Recent development in stem cell isolation methods and expansion under laboratory conditions create an opportunity to use those aforementioned cells in tissue engineering and regenerative medicine. Particular attention is drawn towards mesenchymal stem cells (MSCs) being multipotent progenitors exhibiting several unique characteristics, including high proliferation potential, self-renewal abilities and multilineage differentiation into cells of mesodermal and non-mesodermal origin. High abundance of MSCs found in adipose tissue makes it a very attractive source of adult stem cells for further use in regenerative medicine applications. Despite immunomodulating properties of adipose-derived stem cells (ASCs) and a secretion of a wide variety of paracrine factors that facilitate tissue regeneration, effectiveness of stem cell therapy was not supported by the results of clinical trials. Lack of a single, universal stem cell marker, patient-to-patient variability, heterogeneity of ASC population combined with multiple widely different protocols of cell isolation and expansion hinder the ability to precisely identify and analyze biological properties of stem cells. The above issues contribute to conflicting data reported in literature. We will review the comprehensive information concerning characteristic features of ASCs. We will also review the regenerative potential and clinical application based on various clinical trials.


Subject(s)
Adipocytes/cytology , Adipose Tissue/cytology , Mesenchymal Stem Cells/cytology , Stem Cell Transplantation , Animals , Cell Differentiation , Cell Proliferation , Cellular Senescence , Clinical Trials as Topic , Humans , Mice , Phenotype , Regenerative Medicine/methods , Stromal Cells/cytology
3.
Biosci Rep ; 35(3)2015 May 14.
Article in English | MEDLINE | ID: mdl-26182374

ABSTRACT

Adipose-derived stem cells (ASCs) possess a high differentiation and proliferation potential. However, the phenotypic characterization of ASCs is still difficult. Until now, there is no extensive analysis of ASCs markers depending on different liposuction methods. Therefore, the aim of the present study was to analyse 242 surface markers and determine the differences in the phenotypic pattern between ASCs obtained during mechanical and ultrasound-assisted liposuction. ASCs were isolated from healthy donors, due to mechanical and ultrasound-assisted liposuction and cultured in standard medium to the second passage. Differentiation potential and markers expression was evaluated to confirm the mesenchymal nature of cells. Then, the BD LyoplateTM Human Cell Surface Marker Screening Panel was used. Results shown that both population of ASCs are characterized by high expression of markers specific for ASCs: cluster of differentiation (CD)9, CD10, CD34, CD44, CD49d, CD54, CD55, CD59, CD71 and low expression of CD11a, CD11c and CD144. Moreover, we have noticed significant differences in antigen expression in 58 markers from the 242 studied. Presented study shows for the first time that different liposuction methods are not a significant factor which can influence the expression of human ASCs surface markers.


Subject(s)
Adipose Tissue/cytology , Biomarkers/metabolism , Lipectomy/methods , Stem Cells/physiology , Adipocytes , Adipogenesis/physiology , Adult , Antigens, CD/metabolism , Cell Differentiation , Cells, Cultured , Humans , Osteogenesis/physiology , Phenotype , Stem Cells/cytology , Ultrasonography, Interventional/methods
4.
Expert Opin Biol Ther ; 14(6): 831-9, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24655038

ABSTRACT

INTRODUCTION: The first application of tissue engineering was based on the use of differentiated cells from the adult organism, which was associated with an invasiveness and high risk of diseased cells' transplantation. Over the years, the range of available cell populations for tissue engineering has widened. AREAS COVERED: We review the comprehensive information concerning the characteristic features of amniotic-fluid-derived stem cells (AFSCs). We also review the potential applications of these cells in clinical practice. EXPERT OPINION: AFSCs hold promise for the future treatment of many incurable diseases. However, such cell-based therapies have some limitations, and there are questions relating to the use of stem cells, which should be carefully analyzed before translation of these cells into clinical practice.


Subject(s)
Amniotic Fluid/cytology , Cell Separation , Regenerative Medicine/methods , Stem Cell Transplantation , Stem Cells/physiology , Tissue Engineering/methods , Animals , Biomarkers/metabolism , Cell Differentiation , Cell Lineage , Cell Proliferation , Female , Humans , Phenotype , Pregnancy , Stem Cells/metabolism
5.
Acta Pol Pharm ; 70(1): 153-61, 2013.
Article in English | MEDLINE | ID: mdl-23610971

ABSTRACT

With the object of improving the effectiveness of a malignant melanoma's treatment and a patients' quality of life, there is a serious need to identify new anticancer compounds, for example, among naturally derived compounds such as sodium butyrate. The aim of this study was to assess the combined impact of carboplatin (C) and sodium butyrate on the B16 melanoma viability by in vitro. B16 cell line was exposed to various concentrations of carboplatin (0.001-10 micromol/L) and sodium butyrate (1 to 100 mmol/L) for 24 h. LC10, LC50 and LC90 values were calculated. The influence of carboplatin and sodium butyrate on the cell cycle and apoptosis was assessed. Additionally, magnetic stem cell sorting was performed, positive melanoma CD133 cells were isolated and the effects of carboplatin and sodium butyrate on cell viability with heterogeneous population of melanoma cells (CD133+/CD133-) was compared. For carboplatin LC50 and LC90 were 1.2 micromol/L and 4.58 pmol/L, respectively. For sodium butyrate LC50 and LC90 were 65.73 mmol/L and 275.06 mmol/L. The value for LC10 could not be determined. Sodium butyrate at the highest concentration (100.0 mmol/L) resulted in only 57.36% mortality of cells. A synergistic effect of both compounds was observed in low concentrations of sodium butyrate and carboplatin. That synergism disappeared at concentrations corresponding to LC50. At the concentration corresponding to LC50 C and high concentration of sodium butyrate, a decrease of cell numbers in phase G2/M was observed (r = -0.97). Cells were arrested in phase G1/G0 and S. The presented results exclude the possibility of the combined application of sodium butyrate and carboplatin in cancer therapy.


Subject(s)
Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Butyrates/pharmacology , Carboplatin/pharmacology , Histone Deacetylase Inhibitors/pharmacology , Melanoma, Experimental/pathology , AC133 Antigen , Animals , Antigens, CD/metabolism , Apoptosis/drug effects , Biomarkers, Tumor/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Synergism , Glycoproteins/metabolism , Immunomagnetic Separation , Melanoma, Experimental/immunology , Mice , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/immunology , Neoplastic Stem Cells/pathology , Peptides/metabolism , Time Factors
6.
Int J Oncol ; 41(6): 1943-9, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23042104

ABSTRACT

Lung cancer is one of the most common tumors and its treatment is still inefficient. In our previous work we proved that ciprofloxacin has a different influence on five cancer cell lines. Here, we aimed to compare the biological effect of ciprofloxacin on cell lines representing different responses after treatment, thus A549 was chosen as a sensitive model, C6 and B16 as highly resistant. Three different cell lines were analyzed (A549, B16 and C6). The characterization of continuous cell growth was analyzed with the Real-Time Cell Analyzer (RTCA)-DP system. Cytoskeletal changes were demonstrated using immunofluorescence. The cell cycle was analyzed using flow cytometry. Ciprofloxacin was cytostatic only against the A549 cell line. In the case of other tested cell lines a cytostatic effect was not observed. Cytoskeletal analysis confirms the results obtained with RTCA-DP. A549 cells were inhibited in the G2/M phase suggesting a mechanism related to topoisomerase II inhibition. The biological effects of ciprofloxacin support the hypothesis that this drug can serve as an adjuvant treatment for lung cancer, due to its properties enabling topoisomerase II inhibition.


Subject(s)
Antineoplastic Agents/pharmacology , Carcinoma, Non-Small-Cell Lung/enzymology , Ciprofloxacin/pharmacology , DNA Topoisomerases, Type II/metabolism , Lung Neoplasms/enzymology , Topoisomerase II Inhibitors/pharmacology , Actins/metabolism , Animals , Carcinoma, Non-Small-Cell Lung/drug therapy , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Humans , Lung Neoplasms/drug therapy , Mice , Rats
7.
Aging Clin Exp Res ; 24(5): 404-11, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22595834

ABSTRACT

Mesenchymal stem cells (MSCs) are in the center of attention of many investigators due to easy isolation from many tissues. MSC capability to differentiate into many cell types makes them a starting point of many new therapies, especially in tissue engineering. However, understanding the process of MSC aging is crucial for selecting donors for cellular therapies, which is necessary for successful treatment. Cell changes can be divided into three major groups. Changes which affect their proliferate rate, differentiation capability and genome stability lead to decrease of their usefulness in new therapies. There are many tools that can be used to describe and measure some features of aging in MSCs but the essence of this process is still unclear. The aim of this review is to take a deep look into the influence of donor age and in vitro aging on MSC properties.


Subject(s)
Aging , Antioxidants/metabolism , Cellular Senescence , Mesenchymal Stem Cells/cytology , Animals , Female , Free Radical Scavengers/metabolism , Free Radicals/metabolism , Humans , Male , Mice , Mitochondria/metabolism , Oxidative Stress , Oxygen/metabolism , Rats , Sex Factors , Steroids/metabolism
8.
Postepy Hig Med Dosw (Online) ; 66: 983-90, 2012 Dec 07.
Article in Polish | MEDLINE | ID: mdl-23687217

ABSTRACT

Circulating tumor cells (CTCs) are cells circulating in the blood, which in terms of antigenic or genetic profile correspond to a particular type of cancer. It is suspected that CTCs possess properties of cancer stem cells. Detection, quantification and characterization of CTCs in the peripheral blood can be of great importance for modern oncology. In the case of early-stage disease, CTCs may help in cancer detection, estimation of metastasis risk and treatment prognosis. In advanced cancer patients, CTCs may also have prognostic significance and may facilitate monitoring response to treatment. Identification of CTCs in the circulation and their differentiation from hematopoietic cells and normal epithelial cells could be based on physical and biological properties such as size, density and expression of specific proteins. Immunomagnetic techniques are the most commonly used methods of CTCs isolation. CellSearch System (CSS) is the only test for detecting CTCs in the peripheral blood approved by the Food and Drug Administration (FDA) for clinical use. The paper presents the characteristics of circulating tumor cell isolation methods and the results of studies concerning CTCs isolation in patients with prostate, bladder and kidney cancer. 


Subject(s)
Biomarkers, Tumor/blood , Neoplastic Cells, Circulating/pathology , Urogenital Neoplasms/blood , Urogenital Neoplasms/pathology , Humans , Immunomagnetic Separation , Prognosis
9.
Acta Pol Pharm ; 68(6): 859-65, 2011.
Article in English | MEDLINE | ID: mdl-22125950

ABSTRACT

Ciprofloxacin is a chemotherapeutic agent mainly used in the treatment of the pulmonary and urinary tract infections but is also known for its anticancer properties. The aim of these study was to check the anticancer effect of ciprofloxacin on selected five cell lines. Human non-small cell lung cancer line A549, human hepatocellular carcinoma line HepG2, human and mouse melanoma lines (A375.S2 and B16) and rat glioblastoma line C6 were used for evaluation of cytotoxic properties of ciprofloxacin (in concentration range: 10-1000 microg/mL). Viability was established using trypan blue assay and MTT. Ciprofloxacin induced morphological changes and decreased viability of A549 cells in a concentration and time dependent manner. In case of A375.S2 and B16 cell lines, cytotoxicyty of ciprofloxacin was observed but we were not able to eradicate all cells from A375.S2 and B16 cultures. HepG2 line was sensitive to ciprofloxacin, but this effect was independent from concentration and incubation time. The C6 cells were insensitive to ciprofloxacin. Our results showed that ciprofloxacin can be potentially used for the experimental adjunctive therapy of lung cancer.


Subject(s)
Ciprofloxacin/pharmacology , Neoplasms/pathology , Animals , Antineoplastic Agents/pharmacology , Brain Neoplasms/pathology , Carcinoma, Hepatocellular/pathology , Carcinoma, Non-Small-Cell Lung/pathology , Cell Shape/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Glioblastoma/pathology , Hep G2 Cells , Humans , Inhibitory Concentration 50 , Liver Neoplasms/pathology , Lung Neoplasms/pathology , Melanoma, Experimental/pathology , Mice , Rats , Time Factors
10.
Postepy Hig Med Dosw (Online) ; 65: 496-500, 2011 Aug 05.
Article in English | MEDLINE | ID: mdl-21918251

ABSTRACT

INTRODUCTION: The subject of the study compare the influences of YC-1 guanylyl cyclase activator with ODQ guanylyl cyclase inhibitor on the tracheal smooth muscle contraction induced by carbachol. The study specified the influence of increasing concentrations of soluble guanylyl cyclase activators YC-1 and 8Br cGMP on the reaction of tracheal smooth muscle contraction released by carbachol. The author also examined the effect of increasing concentrations of soluble guanylyl cyclase inhibitor ODQ on the concentration-effect curves for carbachol. MATERIAL/METHODS: Testing was conducted on an isolated trachea of both sexes of Wistar rats with weight ranging between 350 g and 450 g. Tracheas were prepared in accordance with the Akcasu (1959) method in Szadujkis-Szadurski (1996) modification. Concentration-effect curves were determined with the use of cumulated concentration method, in accordance with the van Rossum method (1963) in Kenakin (2006) modification. RESULTS: According to conducted testing, activation of soluble guanylyl cyclase with the use of YC-1 and 8Br cGMP caused reduced reaction of the tracheal smooth muscle with carbachol on average to 80%. Comparing concentration-effect curves for carbachol before and after the use of 8Br cGMP, similar results were obtained for those released by YC-1. On the other hand, increasing concentrations of guanylyl cyclase inhibitor - ODQ cause shift of curves to the left, decrease of EC(50) value and an increase of maximum reaction to carbachol. CONCLUSIONS: Carbachol, depending on concentration, causes tracheal smooth muscle contraction. According to testing, we can confirm that activation of guanylyl cyclase leads to reduction of the reaction of tracheal smooth muscle to carbachol on average up to 80%


Subject(s)
Enzyme Activators/pharmacology , Guanylate Cyclase/metabolism , Indazoles/pharmacology , Muscle, Smooth/drug effects , Trachea/drug effects , Animals , Carbachol/pharmacology , Cyclic GMP/analogs & derivatives , Cyclic GMP/pharmacology , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Female , Male , Muscle, Smooth/enzymology , Oxadiazoles/pharmacology , Quinoxalines/pharmacology , Rats , Rats, Wistar , Trachea/enzymology
11.
Postepy Hig Med Dosw (Online) ; 65: 569-73, 2011 Sep 05.
Article in English | MEDLINE | ID: mdl-21918260

ABSTRACT

BACKGROUND: The subject of this study is determination of the influence of calmodulin and calcium on gastric fundus smooth muscle contraction. During experiments, the author tested the influence of a serotonin receptor agonist, serotonin (5-HT), causing smooth muscle contraction. MATERIAL/METHODS: Testing was conducted on tissues isolated from rat's stomach. Male Wistar rats with weight between 220 g and 360 g were anesthetized by intraperitoneal injection of urethane (120 mg/kg). The stomach was dissected, and later the gastric fundus was isolated. Tissue was placed in a dish for insulated organs with 20 ml in capacity, filled with Krebs fluid. Results contained in the study are average values ± SE. In order to determine statistical significance, the principles of receptor theory were used (Kenakin modification). RESULTS: According to conducted tests, we can deduce that 8 Br cGMP stops the reaction of gastric fundus smooth muscle contraction induced by serotonin. The use of 8Br-cGMP in the range of concentrations between 10 and 300 µM leads to reduction of maximum effect from 100% to 46%. Similar changes were obtained after the use of guanylate cyclase activator (CG) - YC-1. Curves for the contractile activity of serotonin along with an increase of concentration YC-1 are shifted to the right, and the maximum effect of reaction decreases. Increasing concentrations of flunarizine, a calmodulin antagonist, in a concentration-dependent way blocks binding between calcium and calmodulin, and at the same time leads to the shift of concentration-effect curves for serotonin to the right and a decrease of maximum reaction. Increasing concentrations of ODQ, a guanylate cyclase inhibitor lead to statistically significant shift of the curves to the left, decrease of EC(50) value and simultaneous increase of maximum reaction to serotonin. CONCLUSIONS: According to conducted testing, serotonin causes gastric fundus smooth muscle contraction dependent on concentration. Reaction of contraction induced by serotonin is stopped by a calmodulin antagonist, flunarizine. In addition, experiments confirmed participation of cyclical nucleotides in blocking reaction of gastric fundus contraction.


Subject(s)
Calcium/pharmacology , Calmodulin/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Animals , Gastric Fundus/drug effects , Male , Rats , Rats, Wistar , Serotonin/pharmacology , Statistics as Topic
12.
Med Sci Monit ; 16(10): RA218-23, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20885364

ABSTRACT

Oral ciprofloxacin might achieve higher concentration in urine than in serum; theoretically, this drug might act as an anticancer drug against bladder cancer cells. Among fluoroquinolones, ciprofloxacin is distinguished by strong inhibition of topoisomerase II. A good correlation between cytotoxic activity of ciprofloxacin toward eukaryotic cells and its ability to induce the cleavable complexes topoisomerase II-DNA has been demonstrated. These data provide a basis for supposing that ciprofloxacin may act as anticancer drug. The efforts of evaluating ciprofloxacin's influence on human bladder cell lines have been shown by many authors. The cells were exposed to ciprofloxacin at various concentrations that are attainable in the urine after oral drug administration. Antiproliferative potential of the ciprofloxacin against human bladder cells varies according to drug concentration and time of incubation. It seems that ciprofloxacin can act as an anticancer drug in eukaryotic cells. Low urine pH can enhance the antitumor effect of ciprofloxacin. Ciprofloxacin enhances the effect of action of doxorubicin and epirubicin, which are used to prevent bladder cancer recurrence after transurethral resection of superficial bladder cancer. We think that ciprofloxacin might be used for antibacterial prophylaxis and as an anticancer agent in patients with superficial bladder cancer. This idea must be checked in future placebo controlled trials.


Subject(s)
Anti-Infective Agents/therapeutic use , Carcinoma, Transitional Cell/prevention & control , Ciprofloxacin/therapeutic use , Urinary Bladder Neoplasms/prevention & control , Antineoplastic Agents/therapeutic use , Carcinoma, Transitional Cell/drug therapy , Cell Line, Tumor , Ciprofloxacin/pharmacology , Dose-Response Relationship, Drug , Doxorubicin/administration & dosage , Doxorubicin/therapeutic use , Drug Screening Assays, Antitumor , Drug Therapy, Combination , Epirubicin/administration & dosage , Epirubicin/pharmacology , Epirubicin/therapeutic use , Humans , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/prevention & control , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/pathology
13.
Pulm Pharmacol Ther ; 23(5): 373-5, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20211752

ABSTRACT

Ciprofloxacin is an antibiotic that belongs to fluoroquinoles, characterized by broad spectrum of action against pathogens, especially Gram(-) aerobic bacilli. For a long time, it has been thought that ciprofloxacin has an effect only on bacterial cells. Now it is known, that this drug can significantly affect eukaryotic cells including human cancer cells. Its bactericidal action relay on inhibition of topoisomerase II, enzyme responsible for alterations in 3D structure of DNA during replication, transcription and chromatin condensation. Thanks to that, ciprofloxacin can induce cell cycle arrest and apoptosis of cancer cells. The effectiveness of ciprofloxacin was confirmed in several in vitro studies on tumor cell lines such as: human bladder cells, leukaemic cell lines, human osteosarcoma cells, human prostate cancer cells, human colorectal carcinoma cells and human non-small cell lung cancer cell line. Ciprofloxacin is particularly effective against non-small cell lung cancer mainly due to accumulation of ciprofloxacin in lung tissue after intravenous administration and its toxicity against lung cancer lines in vitro in a concentration and time-dependent manner.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Cycle/drug effects , Ciprofloxacin/pharmacology , Fluoroquinolones/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis/physiology , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Ciprofloxacin/therapeutic use , Dose-Response Relationship, Drug , Fluoroquinolones/therapeutic use , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Topoisomerase II Inhibitors/pharmacology , Topoisomerase II Inhibitors/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...